Pulse Biosciences Prioritizes nPulse Cardiac Catheter Ablation System Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy PLSE?
Pulse Biosciences announced a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System. "The European feasibility data from over 150 patients sends a definitive message," said Bob Duggan, co-chairman of Pulse Biosciences. "The nPulse clinical performance demonstrates a clear potential to change clinical practice for the health treatment of millions of patients. Our mission to support this program deserves our highest priority, and we are updating our capital allocation to align with this extraordinary opportunity." This initiative follows the announcement of clinical outcomes from the company's 150-patient European feasibility study, which demonstrated that nsPFA delivers a unique combination of speed, safety, and long-term durable efficacy in treating Atrial Fibrillation. The company said, "The decision to centralize resources on the Cardiac Catheter program is backed by data recently presented at the 31st Annual AF Symposium, which positions nPulse as a best-in-class solution: 100% Procedural Success at 6 Months: 75/75 evaluable patients achieved acute Pulmonary Vein Isolation success. 96% Sustained Success at 12 Months: Long-term follow-up confirmed highly durable Pulmonary Vein Isolation, exceeding traditional expectations in a field where approximately 20-25% recurrence is common. Industry-Leading Procedural Efficiency: Left Atrial Dwell Time: 21.0 +/- 13.3 minutes, this would reduce the time spent inside the heart. Total Procedure Time: Averaged 65 minutes, including only 9.8 minutes of fluoroscopy. Ease of Use: Success was achieved with an average of 16.1 applications per procedure. Safety Profile: A low 1.3% rate of Serious Adverse Events (SAEs) related to the primary safety endpoint. Strategic Resource Alignment: Focus on High-Value Growth. To capitalize on these groundbreaking results, Pulse Biosciences is modifying its capital allocation to prioritize the Electrophysiology market development program: Primary Focus: The majority of R&D and clinical investment is now dedicated to the nPulse Cardiac Catheter program's upcoming pivotal IDE study in the United States and Europe and corresponding regulatory submission. Surgical Program Calibration: While the Company remains committed to the Surgical Clamp IDE enrollment, it will reduce short term market development investments in cardiac surgery. Soft-Tissue Ablation Optimization: Operations for the percutaneous soft-tissue ablation system have been streamlined to reduce spend on sales and marketing and focusing on market development by progressing the Vybrance Percutaneous Electrode System towards an on-label indication for the treatment of benign thyroid nodules, driving real-world utilization data, and validating reimbursement rates, thereby allowing for a reduction in investment that can be redirected to the catheter program."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLSE
Wall Street analysts forecast PLSE stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 19.250
Low
22.00
Averages
22.00
High
22.00
Current: 19.250
Low
22.00
Averages
22.00
High
22.00
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulse Biosciences Appoints New COO
- Executive Appointment: Pulse Biosciences has appointed Liane Teplitsky as Chief Operating Officer, bringing 20 years of experience in medical technology, including her recent role as CEO of Artedrone, which is expected to enhance operational efficiency and market expansion.
- Role Expansion: David Kenigsberg's role has been expanded to full-time Chief Medical Officer, indicating the company's commitment to strengthening its medical leadership, aimed at enhancing product development and clinical strategy to support future business growth.
- Market Performance: In pre-market trading, PLSE shares were priced at $19, down 0.31%, reflecting a cautious market sentiment regarding the company's new appointments, which may impact investor confidence.
- Industry Background: Teplitsky has held senior marketing and commercial leadership roles at Abbott Laboratories and St. Jude Medical, and her extensive industry experience is expected to bring new perspectives and strategic direction to Pulse Biosciences.
See More
Pulse Biosciences Launches Atrial Fibrillation Study with First Patient Enrollment
- Trial Launch: Pulse Biosciences has enrolled the first patients in its pivotal U.S. study NANOPULSE-AF, marking a significant advancement in its atrial fibrillation program, with plans to recruit approximately 215 participants to evaluate the safety and effectiveness of its nPulse Cardiac Catheter System.
- High Success Rate: The system achieved a 96% procedural success rate in its European first-in-human feasibility study without the need for anti-arrhythmic drugs, indicating its potential to transform traditional catheter ablation methods for atrial fibrillation treatment.
- Technological Edge: The nPulse system utilizes nanosecond pulsed field ablation technology, achieving a median left atrial dwell time of 21 minutes and a total procedure time of about 65 minutes, significantly enhancing treatment efficiency while minimizing collateral damage to surrounding cardiac tissue.
- Market Potential: The CTO of Pulse Biosciences noted that the first patient enrollment represents an important step based on early feasibility results, and the company will continue to explore applications of this technology in other soft-tissue ablation markets, further solidifying its market position.
See More
Pulse Biosciences Launches NANOPULSE-AF Study with Promising Initial Results
- Study Launch: Pulse Biosciences has successfully enrolled the first patients at St. Bernards Medical Center in Arkansas, marking the initiation of the NANOPULSE-AF study aimed at evaluating the efficacy of its nPulse™ Cardiac Catheter System for treating drug-resistant paroxysmal atrial fibrillation.
- Exceptional Success Rates: The prior feasibility study demonstrated a 96% procedural success rate and 100% acute success at 12 months for the nPulse™ technology, significantly surpassing the typical 20-25% recurrence rates associated with conventional treatments, highlighting its potential in atrial fibrillation management.
- Integrated Technological Advantages: The nPulse™ system is tightly integrated with Abbott's EnSite X 3D electroanatomical mapping system, providing real-time 3D visualization that enhances catheter navigation and contact assessment, thereby improving treatment accuracy and efficiency, which is expected to transform atrial fibrillation treatment paradigms.
- Future Development Plans: The NANOPULSE-AF study plans to enroll approximately 215 participants across up to 30 centers in the U.S. and Europe, with primary endpoints assessed at 6 and 12 months post-ablation to support the broader clinical development of the nPulse™ system.
See More
Pulse Biosciences Accelerates Cardiac Catheter Ablation System Development
- Clinical Study Results: Pulse Biosciences has decided to accelerate the development of its Pulse Cardiac Catheter Ablation System based on a European feasibility study that indicates its Nanosecond Pulsed Field Ablation technology offers a unique combination of speed, safety, and long-term efficacy in treating Atrial Fibrillation.
- Efficacy Data: The study revealed that at 12 months, 45 out of 47 patients (96%) achieved durable pulmonary vein isolation, significantly lower than the typical 20%-25% recurrence rate, highlighting the clinical advantages of this technology.
- R&D Investment Focus: Pulse Biosciences stated that the majority of its R&D and clinical investments will now be directed towards the upcoming pivotal IDE study and related regulatory submissions, aiming to expedite the product's market entry.
- Market Outlook: With advancements in the nPulse platform's clinical milestones, Pulse Biosciences plans to target CE Mark submission in 2026, further solidifying its market position in cardiac treatment.
See More
Pulse Biosciences Accelerates Development of Cardiac Catheter System
- Breakthrough Clinical Data: Pulse Biosciences' European feasibility study involving 150 patients demonstrated a 100% procedural success rate, with all 75 evaluable patients achieving acute Pulmonary Vein Isolation, indicating the potential to transform clinical practices in atrial fibrillation treatment.
- Significant Long-term Efficacy: Follow-up at 12 months revealed a 96% sustained success rate for Pulmonary Vein Isolation, significantly exceeding the traditional 20-25% recurrence rates, suggesting a strong market acceptance for this innovative treatment.
- Strategic Resource Realignment: The company is reallocating the majority of its R&D and clinical investments to focus on the nPulse Cardiac Catheter program, planning pivotal IDE studies in the U.S. and Europe, reflecting a strong commitment to the electrophysiology market and aiming for expedited product commercialization.
- Upcoming Milestones: Pulse Biosciences is set to present late-breaking clinical data on AFib treatment at the 2026 Heart Rhythm Conference, which is expected to further validate the efficacy and safety of its technology, potentially attracting significant investor and medical community interest.
See More
Pulse Biosciences Accelerates Development of Cardiac Catheter System
- Clinical Data Breakthrough: Pulse Biosciences' European feasibility study involving 150 patients demonstrated a 100% procedural success rate, with all 75 evaluable patients achieving acute Pulmonary Vein Isolation (PVI), indicating the potential to transform clinical practices in atrial fibrillation treatment.
- Significant Long-Term Efficacy: Follow-up at 12 months revealed a 96% sustained success rate for PVI, significantly exceeding the traditional 20-25% recurrence rates, thereby establishing the technology's leading position in the electrophysiology field.
- Strategic Resource Realignment: The company is reallocating the majority of its R&D and clinical investments to the upcoming pivotal IDE study for the nPulse Cardiac Catheter in the U.S. and Europe, aiming to accelerate market development and optimize capital allocation to seize high-value growth opportunities.
- Upcoming Milestones: Late-breaking clinical data on the nPulse Cardiac Catheter System will be presented at the Heart Rhythm 2026 conference, further validating its efficacy in treating atrial fibrillation and likely attracting increased investor interest.
See More
Pulse Biosciences Appoints New COO
- Executive Appointment: Pulse Biosciences has appointed Liane Teplitsky as Chief Operating Officer, bringing 20 years of experience in medical technology, including her recent role as CEO of Artedrone, which is expected to enhance operational efficiency and market expansion.
- Role Expansion: David Kenigsberg's role has been expanded to full-time Chief Medical Officer, indicating the company's commitment to strengthening its medical leadership, aimed at enhancing product development and clinical strategy to support future business growth.
- Market Performance: In pre-market trading, PLSE shares were priced at $19, down 0.31%, reflecting a cautious market sentiment regarding the company's new appointments, which may impact investor confidence.
- Industry Background: Teplitsky has held senior marketing and commercial leadership roles at Abbott Laboratories and St. Jude Medical, and her extensive industry experience is expected to bring new perspectives and strategic direction to Pulse Biosciences.
See More
Pulse Biosciences Launches Atrial Fibrillation Study with First Patient Enrollment
- Trial Launch: Pulse Biosciences has enrolled the first patients in its pivotal U.S. study NANOPULSE-AF, marking a significant advancement in its atrial fibrillation program, with plans to recruit approximately 215 participants to evaluate the safety and effectiveness of its nPulse Cardiac Catheter System.
- High Success Rate: The system achieved a 96% procedural success rate in its European first-in-human feasibility study without the need for anti-arrhythmic drugs, indicating its potential to transform traditional catheter ablation methods for atrial fibrillation treatment.
- Technological Edge: The nPulse system utilizes nanosecond pulsed field ablation technology, achieving a median left atrial dwell time of 21 minutes and a total procedure time of about 65 minutes, significantly enhancing treatment efficiency while minimizing collateral damage to surrounding cardiac tissue.
- Market Potential: The CTO of Pulse Biosciences noted that the first patient enrollment represents an important step based on early feasibility results, and the company will continue to explore applications of this technology in other soft-tissue ablation markets, further solidifying its market position.
See More
Pulse Biosciences Launches NANOPULSE-AF Study with Promising Initial Results
- Study Launch: Pulse Biosciences has successfully enrolled the first patients at St. Bernards Medical Center in Arkansas, marking the initiation of the NANOPULSE-AF study aimed at evaluating the efficacy of its nPulse™ Cardiac Catheter System for treating drug-resistant paroxysmal atrial fibrillation.
- Exceptional Success Rates: The prior feasibility study demonstrated a 96% procedural success rate and 100% acute success at 12 months for the nPulse™ technology, significantly surpassing the typical 20-25% recurrence rates associated with conventional treatments, highlighting its potential in atrial fibrillation management.
- Integrated Technological Advantages: The nPulse™ system is tightly integrated with Abbott's EnSite X 3D electroanatomical mapping system, providing real-time 3D visualization that enhances catheter navigation and contact assessment, thereby improving treatment accuracy and efficiency, which is expected to transform atrial fibrillation treatment paradigms.
- Future Development Plans: The NANOPULSE-AF study plans to enroll approximately 215 participants across up to 30 centers in the U.S. and Europe, with primary endpoints assessed at 6 and 12 months post-ablation to support the broader clinical development of the nPulse™ system.
See More
Pulse Biosciences Accelerates Cardiac Catheter Ablation System Development
- Clinical Study Results: Pulse Biosciences has decided to accelerate the development of its Pulse Cardiac Catheter Ablation System based on a European feasibility study that indicates its Nanosecond Pulsed Field Ablation technology offers a unique combination of speed, safety, and long-term efficacy in treating Atrial Fibrillation.
- Efficacy Data: The study revealed that at 12 months, 45 out of 47 patients (96%) achieved durable pulmonary vein isolation, significantly lower than the typical 20%-25% recurrence rate, highlighting the clinical advantages of this technology.
- R&D Investment Focus: Pulse Biosciences stated that the majority of its R&D and clinical investments will now be directed towards the upcoming pivotal IDE study and related regulatory submissions, aiming to expedite the product's market entry.
- Market Outlook: With advancements in the nPulse platform's clinical milestones, Pulse Biosciences plans to target CE Mark submission in 2026, further solidifying its market position in cardiac treatment.
See More
Pulse Biosciences Accelerates Development of Cardiac Catheter System
- Breakthrough Clinical Data: Pulse Biosciences' European feasibility study involving 150 patients demonstrated a 100% procedural success rate, with all 75 evaluable patients achieving acute Pulmonary Vein Isolation, indicating the potential to transform clinical practices in atrial fibrillation treatment.
- Significant Long-term Efficacy: Follow-up at 12 months revealed a 96% sustained success rate for Pulmonary Vein Isolation, significantly exceeding the traditional 20-25% recurrence rates, suggesting a strong market acceptance for this innovative treatment.
- Strategic Resource Realignment: The company is reallocating the majority of its R&D and clinical investments to focus on the nPulse Cardiac Catheter program, planning pivotal IDE studies in the U.S. and Europe, reflecting a strong commitment to the electrophysiology market and aiming for expedited product commercialization.
- Upcoming Milestones: Pulse Biosciences is set to present late-breaking clinical data on AFib treatment at the 2026 Heart Rhythm Conference, which is expected to further validate the efficacy and safety of its technology, potentially attracting significant investor and medical community interest.
See More
Pulse Biosciences Accelerates Development of Cardiac Catheter System
- Clinical Data Breakthrough: Pulse Biosciences' European feasibility study involving 150 patients demonstrated a 100% procedural success rate, with all 75 evaluable patients achieving acute Pulmonary Vein Isolation (PVI), indicating the potential to transform clinical practices in atrial fibrillation treatment.
- Significant Long-Term Efficacy: Follow-up at 12 months revealed a 96% sustained success rate for PVI, significantly exceeding the traditional 20-25% recurrence rates, thereby establishing the technology's leading position in the electrophysiology field.
- Strategic Resource Realignment: The company is reallocating the majority of its R&D and clinical investments to the upcoming pivotal IDE study for the nPulse Cardiac Catheter in the U.S. and Europe, aiming to accelerate market development and optimize capital allocation to seize high-value growth opportunities.
- Upcoming Milestones: Late-breaking clinical data on the nPulse Cardiac Catheter System will be presented at the Heart Rhythm 2026 conference, further validating its efficacy in treating atrial fibrillation and likely attracting increased investor interest.
See More
